1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B1F52DE13D489E4500258A070040D4E0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rare-disease-msl-team-excellence-benchmarking-staffing-roles-recruitment-development-retention-field-success
18
19
20100.28.0.143
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Field Medical Excellence

Rare Disease MSL Team Excellence: Benchmarking Staffing, Roles, Recruitment, Development, Retention, and Field Success

ID: POP-365


Features:

26 Info Graphics

25 Data Graphics

300+ Metrics

76 Narratives


Pages: 58


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Field medical teams within rare disease organizations shoulder greater responsibility in nurturing collaborative relationships with influential KOLs and HCPs. In a changing engagement model, rare disease field medical leaders must ensure their roles, expectations and performance are well-aligned to best support stakeholders, meet needs, and deliver unparalleled value.

Best Practices, LLC conducted this new benchmarking research to identify current and emerging trends around managing field-based, hybrid and virtual MSLs in rare diseases. Insights in this report will help rare disease field medical leaders in improving MSL retention, offering competitive salaries, adjusting staffing levels, ensuring effective engagement strategies and access to key external experts, and quantifying field performance and its impact.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical


Companies Profiled:
Alexion Pharmaceuticals; Amicus Therapeutics; Astellas; Bayer; Biogen; BioMarin; Bluebird Bio; Chiesi; CSL Behring; Dompé; Galapagos; Horizon Therapeutics; Ipsen; Kyowa Kirin; Novartis; Orchard Therapeutics; Sage Therapeutics; Servier; Supernus; Takeda Pharmaceuticals; Ultragenyx; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 22 top Rare Disease manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Key topics covered in this report include:

  • Rare Disease Staffing Levels: Traditional MSLs vs. Hybrid MSLs
  • Drivers of Rare Disease Field Team Evolution
  • Medical vs. Commercial Field Resourcing
  • Effective Recruitment in Rare Disease Segment: Factors and Tactics
  • MSL Training Areas in Rare Disease Segment
  • MSL Salary Levels and Trends in Rare Disease Segment
  • Effective Perks and Retention Strategies in Rare Disease Therapeutic Area
  • Field Challenges
  • KOL Access - Post Pandemic
  • Customer Engagement Preference
  • Proactive Outreach
  • F2F Meetings: Value and Ideal Mix

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Field-based vs. Hybrid MSLs: Some 72% of organizations make use of traditional “field-based” MSLs, while another 56% use “hybrid” MSLs – but few organizations use both types in a strategically complementary manner. For many companies, the difference between field-based and hybrid MSLs is largely a semantic, as both types tend to operate in a similar manner.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-19
II.
Evolving Field Team Roles, Staffing & EngagementPg. 20-30
III.
Recruiting & Retaining MSLsPg. 31-44
IV.
Field Medical KPIsPg. 45-57
V.
About Best Practices, LLCPg. 58

    List of Charts & Exhibits

    I. Executive Summary

    • Project background
    • Key study definitions
    • Benchmark study partners - Rare disease segment
    • Key takeaways for rare disease manufacturers
    • Rare disease executive field performance dashboard
    • Full data summary
    • Field-based vs. hybrid MSLs - Rare disease segment
    • F2F vs. virtual interactions - Rare disease segment
    • Effective recruitment and retention principles in rare disease segment

    II. Evolving Field Team Roles, Staffing & Engagement

    • Prevalence of rare disease MSL types across the industry – Field-based MSLs vs. Hybrid MSLs vs. Virtual MSLs
    • Case study: Large US pharma organization pilot
    • Average staffing levels at rare disease field medical groups
    • Assessing effectiveness of different MSL types in rare disease segment
    • Post-Pandemic drivers of field team evolution
    • Anticipated MSL staffing trends in rare disease segment
    • Average staffing levels for non-MSL field roles in rare disease segment
    • Key field support roles in rare disease therapeutic area
    • Sales rep-to-MSL ratio in rare disease therapeutic area

    III. Recruiting & Retaining MSLs

    • Overall YoY attrition rate among rare disease MSLs
    • Successful MSL recruitment factors
    • Effective tactics to recruit MSLs in rare disease segment
    • Lessons learned in rare disease MSL recruitment
    • MSL training for essential field skills in rare disease therapeutic area
    • Average rare disease MSL salary levels
    • Drivers of MSL compensation
    • Anticipated MSL salary trends
    • Defending increased field team investment
    • Effective perks in attracting new MSLs and retaining existing staff
    • Top MSL retention strategies in rare disease segment

    IV. Field Medical KPIs

    • Top challenges faced by rare disease field teams in supporting external stakeholders
    • Post-Pandemic KOL and HCP access
    • KOL and HCP engagement preferences
    • Average KOL call list size in rare disease segment
    • Total monthly in-person and virtual meetings with KOLs
    • Proactive outreaches to KOLs in rare disease therapeutic area
    • Rare disease MSL proactivity index
    • Interview narrative around proactive outreach
    • Value of F2F meetings in rare disease MSL scorecard
    • Ideal mix of F2F interactions
    • Interview narratives around top KPIs used to demonstrate field impact
    • Effective KPIs used to measure field impact